{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMNATRE5/ec0c624e-7c62-4fe7-99fe-cf05ce5b0618/HTML","dcterms:extent":"22 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMNATRE5/9a43343e-c0b0-41cc-95fd-4b2cded15212/PDF","dcterms:extent":"148 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMNATRE5/8146d902-19a2-4c4a-bd5c-e1c1b80a6fb3/TEXT","dcterms:extent":"14 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-CMNATRE5","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2004","dc:creator":["Banev, Sašo","Ilievska Poposka, Biljana","Petrusevska, Gordana","Smickova, Snežana","Spirovski, Zoran"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:38"},{"@xml:lang":"sl","#text":"5 strani"},{"@xml:lang":"sl","#text":"str. 131-135"}],"dc:identifier":["ISSN:1318-2099","COBISSID:18167257","URN:URN:NBN:SI:doc-CMNATRE5"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"sl","#text":"biokemija"},{"@xml:lang":"en","#text":"diagnostika"},{"@xml:lang":"en","#text":"Immunohistochemistry"},{"@xml:lang":"sl","#text":"Imunohistokemija"},{"@xml:lang":"en","#text":"Lung Neoplasms"},{"@xml:lang":"en","#text":"Neoplasm Staging"},{"@xml:lang":"sl","#text":"Novotvorba, stadij"},{"@xml:lang":"sl","#text":"novotvorbe"},{"@xml:lang":"en","#text":"Pathology"},{"@xml:lang":"sl","#text":"Pljučne novotvorbe"},{"@xml:lang":"sl","#text":"pljučni rak"},{"@xml:lang":"en","#text":"Prognosis"},{"@xml:lang":"sl","#text":"Prognoza"},{"@xml:lang":"sl","#text":"proteini"},{"@xml:lang":"en","#text":"Proto-Oncogene Proteins C-Erbb-2"},{"@xml:lang":"en","#text":"tumor"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Immunohistochemical expression of HER-2/neu in patients with lung carcinoma and its prognostic significance|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. The HER-2 protein or p185her2 is a membrane receptor with tyrosinekinase activity encoded by HER-2/neu gene. Overexpression of HER-2/neuhas been observed in many human cancers, including lung cancer. In the study, the expression of HER-2 protein is determined in the spectrum of lung cancer (adenocarcinoma, sguamous cell carcinoma and small cell carcinoma). Patients and methods. The study population consisted of two groups: 19 patients that had undergone surgical treatment and 10 patients thathad undergone fiber-optic bronchoscopy and biopsy for primary diagnosis only. Tissue specimens were neutral formaldehyde fixed and paraffin-embedded. Standard histochemical and immunohistochemical staining were used for diagnosis. Expression of HER-2/neu protein was determined by immunohistochemical staining with Hercep TestT`` (DAKO). The results were graded 0-1 as negative and 2-3 as positive. Results. Overall incidence of HER-2/neu overexpression was 34.4% (10 of 29). Higher incidence was found in the patients with adenocarcinoma 45.4% (5 of 11). In squamous cell carcinoma and small cell carcinoma, the overexpression incidence was 30.7% (4 of 13) and20% (1 of 5), respectively. No statistically significant difference was seen given the age and gender. HER-2/neu overexpression was more pronounced inthe patients with advanced tumour: all patients with squamous cell carcinomaand HER-2/neu overexpression had stage IIIB and stage IV disease, while 80% of adenocarcinoma patients with HER-2/neu overexpression had stage IIIA and IIIB disease. Conclusions. These results are satisfactory and encourage us to continue this work in the follow-up study to evaluate HER-2/neu role as predictive and prognostic factor for the patients with lung cancer"},{"@xml:lang":"sl","#text":"Izhodišča. Protein HER-2 ali p185her2 je membranski receptor s tirozinsko kinazno aktivnostjo, ki je določena z genom HER-2/neu. Prekomerno aktivnost HER-2/neu lahko zasledimo pri bolnikih z različnimi onkološkimi obolenji, takotudi pri raku pljuč. Ker obstajajo različna poročila o stopnji aktivnosti tega gena pri pljučnem raku, smo v raziskavi določali protein HER-2 pri bolnikih z žleznim, skvamoznoceličnim in drobnoceličnim pljučnim rakom. Bolniki in metode. Protein HER-2 smo določali pri tumorjih 29 bolnikov s pljučnim rakom; 19 bolnikov je bilo operiranih, pri 10 pa smo tumorsko tkivo dobili ob diagnostičnem postopku z upogljivim bronhoskopom preden smo jih zdravili s kemo/radioterapijo. Vzorce tkiva smo fiksirali v nevtralnem formalinu in naredili parafinske preparate. Za diagnosticiranje smo uporabljali standardna histokemična in imunohistokemična barvanja. Prisotnost proteina HER-2/neu smo potrjevali z imunohistokemičnim barvilom s pomočjo Hercep Testa (DAKO). Rezultate testiranja smo označili s stopnjami od 0 do 3. Stopnjo 0 in 1 smo ocenili kot negativno, s stopnjo 2 ali 3 pa kot pozitivno. Rezultati. Prekomerno izraženost proteina HER-2/neu smo zasledili v 34,4% (pri10 od 29 bolnikov). V večji meri smo ga ugotovili pri bolnikih z žleznim rakom in to v 45,4% (pri 5 od 11 bolnikov), pri bolnikih s skvamoznoceličnim rakom pa v 30,7% (4 od 13 bolnikov) in pri bolnikih z drobnoceličnim rakom le v 20% (1 od 5 bolnikov). Glede na starost in spol nismo našli statistično značilnih razlik. Pri napredovalih oblikah bolezni smo ugotovili večjo izraženost proteina HER2/neu, saj so imeli vsi bolniki s skvamoznoceličnim rakom pljuč in stadijem bolezni IIIB in IV povišan protein, bolniki z žleznim karcinomom in stadijem IIIB in IV pa v 80%. Zaključki. Obetajoči rezultati kažejo, da bi lahko imel HER-2/neu pri bolnikih s pljučnim rakom prediktivni in prognostični pomen, kar bomo poskusili potrditi po daljšem spremljanju bolnikov"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-CMNATRE5","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-CMNATRE5"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMNATRE5/9a43343e-c0b0-41cc-95fd-4b2cded15212/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-CMNATRE5/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-CMNATRE5"}}}}